Date: 2012-10-23
Type of information: Production agreement
Compound: anti-cancer stem cell therapeutics including Demcizumab,Anti-Notch 2/3 (OMP-59R5), Anti-Fzd7 (OMP-18R5), Anti-Notch1 (OMP-52M51), Anti-DLL4/VEGF Bi-Specific
Company: Lonza (Switzerland) Oncomed Pharmaceuticals (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
manufacturing
production
Action mechanism:
Disease:
Details: Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, have announced an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.
Under the agreement, Lonza will produce material at its mammalian manufacturing facility in Slough, UK. The multi-product GS System™ License provides access to Lonza’s GS Gene Expression System™ and Version 8 Media and Feeds Manufacturing Platform.
OncoMed’s pipeline is focused on the development of novel monoclonal antibodies that target cancer stem cells. The Process Development and Manufacturing Collaboration includes, but is not limited to, the following OncoMed projects:
• Demcizumab (Anti-DLL4, OMP-21M18), currently in Phase 1b
• Anti-Notch 2/3 (OMP-59R5), currently in Phase 1b/2
• Anti-Fzd7 (OMP-18R5), currently in Phase 1
• Anti-Notch1 (OMP-52M51), currently in Phase 1
• Anti-DLL4/VEGF Bi-Specific, currently in preclinical testing.
Financial terms:
Latest news:
